313 related articles for article (PubMed ID: 26210103)
41. [Current status of castration resistant prostate cancer basic research].
Sakamoto S; Ichikawa T
Nihon Rinsho; 2014 Dec; 72(12):2097-102. PubMed ID: 25518340
[TBL] [Abstract][Full Text] [Related]
42. The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.
VanderWeele DJ
Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-3. PubMed ID: 26452188
[No Abstract] [Full Text] [Related]
43. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Cheng HH; Abida W; Ellis L; Harshman LC; Spratt DE; Simons JW; Pienta KJ; Soule HR
Prostate; 2017 Nov; 77(15):1478-1488. PubMed ID: 28925066
[TBL] [Abstract][Full Text] [Related]
44. DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
Warner EW; Yip SM; Chi KN; Wyatt AW
BJU Int; 2019 May; 123(5):769-776. PubMed ID: 30281887
[TBL] [Abstract][Full Text] [Related]
45. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
46. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
47. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
48. [Molecular biology of castration resistant prostate cancer.].
Medina-López RA; Tarón M; Osman-García I; Duran I
Arch Esp Urol; 2018 Sep; 71(8):639-650. PubMed ID: 30319124
[TBL] [Abstract][Full Text] [Related]
49. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
50. [Gene therapy for castration resistant prostate cancer].
Nasu Y
Nihon Rinsho; 2014 Dec; 72(12):2152-7. PubMed ID: 25518350
[TBL] [Abstract][Full Text] [Related]
51. Genomic landscape of salivary gland tumors.
Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R
Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885
[TBL] [Abstract][Full Text] [Related]
52. New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer.
Conteduca V; Mosca A; Brighi N; de Giorgi U; Rescigno P
Cells; 2021 Jan; 10(1):. PubMed ID: 33478015
[TBL] [Abstract][Full Text] [Related]
53. Molecular landscape of pancreatic cancer: implications for current clinical trials.
Heestand GM; Kurzrock R
Oncotarget; 2015 Mar; 6(7):4553-61. PubMed ID: 25714017
[TBL] [Abstract][Full Text] [Related]
54. [Advances in the studies of androgen metabolism and de novo androgen synthesis in castration resistant prostate cancer].
Wang B; Wu KJ; He DL
Zhonghua Nan Ke Xue; 2013 Aug; 19(8):736-41. PubMed ID: 24010211
[TBL] [Abstract][Full Text] [Related]
55. Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Georgi B; Korzeniewski N; Hadaschik B; Grüllich C; Roth W; Sültmann H; Pahernik S; Hohenfellner M; Duensing S
Int J Oncol; 2014 Oct; 45(4):1337-44. PubMed ID: 25070358
[TBL] [Abstract][Full Text] [Related]
56. [Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2014 Dec; 72(12):2186-92. PubMed ID: 25518356
[TBL] [Abstract][Full Text] [Related]
57. Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.
Petrylak DP; Crawford ED
Target Oncol; 2017 Aug; 12(4):401-412. PubMed ID: 28620691
[TBL] [Abstract][Full Text] [Related]
58. Significance of
Chakraborty G; Armenia J; Mazzu YZ; Nandakumar S; Stopsack KH; Atiq MO; Komura K; Jehane L; Hirani R; Chadalavada K; Yoshikawa Y; Khan NA; Chen Y; Abida W; Mucci LA; Lee GM; Nanjangud GJ; Kantoff PW
Clin Cancer Res; 2020 Apr; 26(8):2047-2064. PubMed ID: 31796516
[TBL] [Abstract][Full Text] [Related]
59. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
60. Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise.
Tenuta A; Klotz L; Parker JL
BJU Int; 2014 May; 113(5b):E82-9. PubMed ID: 24053150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
